<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116383</article-id><article-id pub-id-type="publisher-id">ACM-43090</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_99212165.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  妇科恶性肿瘤术后下肢淋巴水肿的研究进展
  Study of Lower Extremity Lymphedema after Surgery for Gynecological Malignant Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>怡林</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>山东第一医科大学(山东省医学科学院)，山东 济南</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2650</fpage><lpage>2655</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  妇科恶性肿瘤治疗原则以手术治疗为主，术后根据指征给予相应的辅助治疗，盆腔淋巴结切除术是妇科恶性肿瘤手术治疗、病理分期、术后辅助治疗指导及预后结局判断的重要组成部分，然而这种损害淋巴系统的手术会导致下肢淋巴水肿(lymphedema of the lower extremity, LLE)，随着妇科癌症发病率和生存率的增加，应优先考虑对慢性并发症LLE的处理。LLE的自然病程包括腿围增加、纤维化、炎症、异常脂肪沉积和最终明显的皮肤病理，严重影响患者的生活质量。临床诊断依赖于病史，肿胀、麻木等临床表现和体格检查及各项辅助检查，患侧与未患侧的等效区域的比较反映了疾病的严重程度。治疗方式包括以复杂的降充血治疗为主的保守物理策略，以及新兴的显微外科治疗、外科干预，以及晚期疾病的吸脂术和还原切除手术。本文就妇科恶性肿瘤术后LLE的发生、危险因素、诊断和治疗现状进行以下综述。
   The treatment principle of gynecological malignant tumors is mainly surgical treatment, and postoperative adjuvant treatment is given according to the indications. Pelvic lymph node resection is an important part of surgical treatment, pathological staging, postoperative adjuvant treatment guidance and prognosis and outcome judgment of gynecological malignant tumors. However, such surgery that damages the lymphatic system may lead to lymphedema of the lower extremity (LLE). With the increase of the incidence and survival rate of gynecological cancer, the management of chronic complication LLE should be given priority. The natural course of disease includes increased limb circumference, fibrosis, inflammation, abnormal fat deposition and finally obvious skin pathology, which seriously affects the quality of life of patients. The clinical diagnosis depends on the history, the clinical manifestations such as swelling and numbness, and the physical examination and various auxiliary examinations. The comparison of the equivalent area between the affected and non-affected sides reflects the severity of the disease. Treatment options include conservative physical strategies characterized by complex decongestant therapy and intermittent pneumatic compression, as well as emerging microsurgical treatments, surgical interventions, and liposuction and reductive resection for advanced disease. This article reviews the occurrence, risk factors, diagnosis and treatment status of postoperative LLE for gynecological malignant tumors.
 
</p></abstract><kwd-group><kwd>妇科恶性肿瘤，淋巴水肿，诊断，治疗, Gynecological Malignant Tumor</kwd><kwd> Lymphedema</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>妇科恶性肿瘤治疗原则以手术治疗为主，术后根据指征给予相应的辅助治疗，盆腔淋巴结切除术是妇科恶性肿瘤手术治疗、病理分期、术后辅助治疗指导及预后结局判断的重要组成部分，然而这种损害淋巴系统的手术会导致下肢淋巴水肿(lymphedema of the lower extremity, LLE)，随着妇科癌症发病率和生存率的增加，应优先考虑对慢性并发症LLE的处理。LLE的自然病程包括腿围增加、纤维化、炎症、异常脂肪沉积和最终明显的皮肤病理，严重影响患者的生活质量。临床诊断依赖于病史，肿胀、麻木等临床表现和体格检查及各项辅助检查，患侧与未患侧的等效区域的比较反映了疾病的严重程度。治疗方式包括以复杂的降充血治疗为主的保守物理策略，以及新兴的显微外科治疗、外科干预，以及晚期疾病的吸脂术和还原切除手术。本文就妇科恶性肿瘤术后LLE的发生、危险因素、诊断和治疗现状进行以下综述。</p></sec><sec id="s2"><title>关键词</title><p>妇科恶性肿瘤，淋巴水肿，诊断，治疗</p></sec><sec id="s3"><title>Study of Lower Extremity Lymphedema after Surgery for Gynecological Malignant Tumor</title><p>Yilin Hu</p><p>Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan Shandong</p><p><img src="//html.hanspub.org/file/25-1572300x4_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 11<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/25-1572300x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The treatment principle of gynecological malignant tumors is mainly surgical treatment, and postoperative adjuvant treatment is given according to the indications. Pelvic lymph node resection is an important part of surgical treatment, pathological staging, postoperative adjuvant treatment guidance and prognosis and outcome judgment of gynecological malignant tumors. However, such surgery that damages the lymphatic system may lead to lymphedema of the lower extremity (LLE). With the increase of the incidence and survival rate of gynecological cancer, the management of chronic complication LLE should be given priority. The natural course of disease includes increased limb circumference, fibrosis, inflammation, abnormal fat deposition and finally obvious skin pathology, which seriously affects the quality of life of patients. The clinical diagnosis depends on the history, the clinical manifestations such as swelling and numbness, and the physical examination and various auxiliary examinations. The comparison of the equivalent area between the affected and non-affected sides reflects the severity of the disease. Treatment options include conservative physical strategies characterized by complex decongestant therapy and intermittent pneumatic compression, as well as emerging microsurgical treatments, surgical interventions, and liposuction and reductive resection for advanced disease. This article reviews the occurrence, risk factors, diagnosis and treatment status of postoperative LLE for gynecological malignant tumors.</p><p>Keywords:Gynecological Malignant Tumor, Lymphedema, Diagnosis, Treatment</p><disp-formula id="hanspub.43090-formula27"><graphic xlink:href="//html.hanspub.org/file/25-1572300x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1572300x7_hanspub.png" /> <img src="//html.hanspub.org/file/25-1572300x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>淋巴水肿是一种液体的异常积累，在妇科癌症中发生在肚脐以下，可累及双侧腿和脚、下腹部、双侧臀部和生殖器 [<xref ref-type="bibr" rid="hanspub.43090-ref1">1</xref>]。与乳腺癌术后上肢淋巴水肿比较，妇科恶性肿瘤术后并发LLE具有起病慢、初期症状不典型特点，容易被患者、医护人员忽视，其早期干预及识别率均不理想。据报道，妇科癌症术后的LLE患病率从5%到58%不等 [<xref ref-type="bibr" rid="hanspub.43090-ref2">2</xref>]，这可能与不同的诊断标准、手术方式和放射治疗以及患者的危险因素存在有关，治疗LLE的关键是早期预防、早期诊断和早期治疗。</p></sec><sec id="s6"><title>2. LLE的发生及危险因素</title><p>妇科恶性肿瘤术后LLE的发生发展是由多因素引起，在妇科恶性肿瘤的手术中，盆腔或腹股沟区淋巴管被切断，导致淋巴回流障碍，淋巴系统无法维持组织液稳态，蛋白液在组织间隙积聚，间质静水压力的增加导致细胞死亡和炎症，随之出现CD4+T细胞浸润，随后成纤维细胞，平滑肌细胞增殖，最后导致脂肪沉积紊乱。淋巴结切除后淋巴管损伤仅是激发因素，随后发生CD4+T细胞介导的慢性炎症反应更增加了淋巴液外渗、减弱了集合淋巴管的泵功能以及使集合淋巴管生成障碍，最终导致纤维化 [<xref ref-type="bibr" rid="hanspub.43090-ref3">3</xref>]。</p><p>有研究表明，接受淋巴结切除术的妇科癌症患者下肢淋巴水肿发生率显著高于前哨淋巴结活检组 [<xref ref-type="bibr" rid="hanspub.43090-ref4">4</xref>]。前哨淋巴结活检作为更广泛的淋巴结清扫的替代方法的出现，使早期干预成为可能。研究表明，更广泛的淋巴结清扫、接受化疗和放疗、肥胖(BMI &gt; 35 kg/m<sup>2</sup>)、体力活动不足、诊断为外阴/阴道癌和治疗前存在淋巴水肿是潜在的危险因素 [<xref ref-type="bibr" rid="hanspub.43090-ref2">2</xref>]。有些病人因遗传原因易患淋巴水肿，少量的研究已经确定了某些控制交际血管生成和淋巴管生成的基因：HGF (编码肝细胞生长因子)或MET (编码受体)和GJC2 (编码联接蛋白47 (也称为缝隙连接γ2蛋白质))，这些基因的罕见突变与发生继发性淋巴水肿的风险增加有关 [<xref ref-type="bibr" rid="hanspub.43090-ref5">5</xref>]。</p></sec><sec id="s7"><title>3. 淋巴水肿的诊断及评估</title><p>早期准确诊断LLE是适当干预和预防晚期疾病不可逆转后遗症的关键。目前LLE诊断主要依靠既往病史、临床表现、体格检查和辅助检查，亚临床期LLE无明显的肿胀、麻木、刺痛和疼痛等临床表现，常难以被发现，淋巴闪烁造影：利用放射性核素锝-99作为淋巴管的示踪分子，以前被认为是淋巴水肿成像的“金标准”，然而，基于放射性核素技术的图像分辨率较低，且只能提供一组静态图像 [<xref ref-type="bibr" rid="hanspub.43090-ref6">6</xref>]。最近，磁共振成像(MRI)因其在不使用放射性同位素的情况下对异常淋巴管显像的高灵敏度而成为诊断淋巴管疾病的一种新方法，MRL的高空间分辨率对淋巴水肿的手术治疗也有深远的影响：MRL可以定位淋巴系统的损伤，以便术前确定适合进行淋巴静脉吻合的血管 [<xref ref-type="bibr" rid="hanspub.43090-ref7">7</xref>]。其他类似于淋巴水肿症状的外周水肿的原因包括慢性静脉功能不全、心/肾衰竭、低白蛋白血症和肥胖等，区分这些和真正的淋巴水肿也很重要，因为病理生理学，管理和可逆性是完全不同的，但是上述的病因也可能同时成为淋巴水肿的危险因素 [<xref ref-type="bibr" rid="hanspub.43090-ref8">8</xref>]。</p><p>LLE可以由测量出的患肢和非患肢的肢间容积差来评估：检测患肢的淋巴水肿体积，并将其与非患肢进行比较，从而定量测量疾病进展或改善情况，目前最常用的肢体容积测量方法有四种：1) 周径测量法；2) 红外线容量分析法；3) 水置换；4) 生物阻抗谱(BIS)，其中红外线容量分析法和BIS广泛应用于上肢。水置换由于不实用和潜在的不精确，已经很大程度上被通过没有弹性的卷尺进行圆周测量所取代。周径测量法是一种最简单、最可行的测量方法，即腿部测量的多个被截锥体的总和，使用截锥体的公式：V = h &#215; (C2 + Cc + c2)/12π (h = 线段高度；C = 线段顶部周长；c = 线段底部周长)计算肢体体积，但当没有标准协议时，这些测量可能是主观的、是不精确的 [<xref ref-type="bibr" rid="hanspub.43090-ref1">1</xref>]。在定义肢体容积变化(limb volume change, LVC) ≥ 5%或10%和最佳定量测量方法上仍存在争议 [<xref ref-type="bibr" rid="hanspub.43090-ref1">1</xref>]，在大多数临床实践和研究中，将基线变化 ≥ 10%作为存在LLE的标准指标。LLE不仅需要定量的客观测量，还需要定性的主观测量，妇科肿瘤淋巴水肿问卷(GCLQ)是在经验证在识别早期发病上肢淋巴水肿的风险患者方面具有预测价值的淋巴水肿乳腺癌问卷的修改，具有良好的敏感性和特异性。</p></sec><sec id="s8"><title>4. 淋巴水肿的分期</title><p>淋巴水肿分期系统是区分疾病严重程度的重要工具，并最终确定适当的治疗方式。国际淋巴协会 [<xref ref-type="bibr" rid="hanspub.43090-ref9">9</xref>] (ISL)将淋巴水肿分成4个阶段。0期：潜伏期或亚临床阶段，尽管淋巴运输受损，但肿胀不存在，该阶段没有明显临床症状，可持续数月甚至数年。I期：富含蛋白的淋巴液在结缔组织中积聚，可见明显肢体肿胀，若抬高肢体，肿胀可以暂时消退，此期可能有凹陷性水肿；II期：上抬肢体时肿胀不会消退，组织开始纤维化，导致肢体变硬；III期：淋巴象皮肿，皮肤非常厚，有巨大皱褶，出现皮肤改变，如脂肪沉积、棘皮症和疣状增生，组织重度纤维化。此分期标准广泛应用在临床和文献报告中。</p></sec><sec id="s9"><title>5. 治疗方法</title><p>LLE属于慢性进行性疾病，目前没有彻底根治的方法，主要的治疗手段是减轻肢体水肿，避免肢体水肿加重，防止出现纤维化等一系列严重的并发症。没有标准的治疗方法适用于所有患者，治疗总体上分为保守治疗和手术治疗。保守治疗可用于绝大多数患者，然而复发率通常较高，需要患者长期的依从性 [<xref ref-type="bibr" rid="hanspub.43090-ref10">10</xref>]，手术治疗适用于水肿程度严重及保守治疗效果不佳的患者。手术治疗方法多种多样，包括切除手术、淋巴静脉吻合术、淋巴管移植术、和淋巴结皮瓣转移等。某些患者淋巴功能已经严重受损，淋巴管吻合术无法成功缓解患者的症状时，最有效的外科治疗仍是减少病变肢体容量的手术。</p><sec id="s9_1"><title>5.1. 保守治疗(非手术治疗)</title><p>1) 手法引流综合消肿疗法，又称综合降充血物理疗法(complete decongestive therapy, CDT)，被认为是治疗淋巴水肿的标准疗法 [<xref ref-type="bibr" rid="hanspub.43090-ref11">11</xref>]。CDT被推荐用于ISL期I-II期淋巴水肿患者，对晚期下肢淋巴水肿的炎症反应和脂肪沉积无治疗作用，CDT包括手法淋巴引流、压缩治疗、功能锻炼、皮肤护理四个部分 [<xref ref-type="bibr" rid="hanspub.43090-ref12">12</xref>]。手法淋巴引流可以调动皮肤，刺激淋巴系统，利用淋巴管和现有的淋巴管静脉吻合术，促进淋巴管流入静脉循环，而不增加过滤，最终促进淋巴循环；压缩治疗通常采用弹力绷带由远心端向近心端对患肢进行环形包扎，且压力逐渐递减，并作为一种反力来对抗随意肌肉活动，从而防止液体的积累，减少组织间液的形成；功能锻炼的方式有下肢抬举运动、髋、膝、踝关节主动运动等，定期运动，以提高肌肉泵的效率，协同增加淋巴循环；下肢淋巴水肿可使患者出现皮肤破裂及感染，应用润肤剂等可有效减少皮肤感染和蜂窝织炎的发生 [<xref ref-type="bibr" rid="hanspub.43090-ref11">11</xref>]。CDT通常分为两个阶段，第一阶段为强化阶段，包括教育、皮肤护理、手工淋巴引流、锻炼和多层压缩包扎，通常持续2至4周。强化治疗阶段后通常紧跟着维持阶段，通过使用压缩服装、皮肤护理、自我手工淋巴引流和家庭锻炼计划优化和保留在强化阶段中获得的变化。此项目国内开展的并不普遍，大部分LLE患者仍得不到有效治疗。保守治疗还包括间歇性气动压缩(Intermittent pneumatic compression, IPC)等，IPC能够促进静脉回流，改善淋巴液血液循环，控制淋巴水肿引起的肿胀，调节淋巴收集功能，并有助于维持强化治疗的结果 [<xref ref-type="bibr" rid="hanspub.43090-ref13">13</xref>]。</p><p>张涤生教授1964年开创烘绑疗法治疗肢体淋巴水肿 [<xref ref-type="bibr" rid="hanspub.43090-ref14">14</xref>]，但近50%的患者因各种原因无法长期坚持治疗，烘绑疗法最大的不足是在治疗期间及刚结束治疗的短时间内，部分患者的水肿肢体由于受热膨胀，会出现短暂变粗的现象，虽然大量临床病例已证明，肿胀会很快消退，且不影响疗效，但是此缺陷会明显影响疗效评估，并降低患者对于疗效的满意度。</p><p>2) 药物治疗</p><p>七叶皂甙钠注射液配合利尿剂治疗被部分国内学者用于治疗下肢淋巴水肿 [<xref ref-type="bibr" rid="hanspub.43090-ref15">15</xref>]，迈之灵是马栗种子提取物，主要有效成分是七叶皂甙，可降低淋巴系统的负荷，改善淋巴及其瓣膜的功能从而促进水肿的消退 [<xref ref-type="bibr" rid="hanspub.43090-ref16">16</xref>]。若患者长期服用利尿剂可能会引发低血压、电解质紊乱等不良反应，现不主张应用。苯并吡喃酮类药物：可激活巨噬细胞，诱导蛋白质降解，促进淋巴液回流。但一项关于苯并吡喃酮对淋巴水肿疗效的系统综述，显示未发现有力证据证明其对减轻淋巴水肿有疗效 [<xref ref-type="bibr" rid="hanspub.43090-ref17">17</xref>]。一些中医特色治疗方法(如穴位针刺、贴敷、中药外敷)及中医院的经验方也对下肢淋巴水肿有一定效果 [<xref ref-type="bibr" rid="hanspub.43090-ref18">18</xref>]。</p></sec><sec id="s9_2"><title>5.2. 手术治疗</title><p>手术治疗主要应用于保守治疗失败的下肢淋巴水肿患者，可大致分为两类，还原疗法如直接切除、抽吸蛋白质脂肪切除(SAPL)等；以及生理外科手术，如淋巴吻合(LVAs)和血管化淋巴结转移(VLNT)等 [<xref ref-type="bibr" rid="hanspub.43090-ref19">19</xref>]，手术治疗对于持续淋巴水肿的患者，特别是复发性蜂窝织炎的患者是很有必要的，但是活动期蜂窝织炎患者禁止手术。对于原发癌症未经治疗或无法控制或局部复发，或医学上不适合安全地接受手术治疗的患者，非手术治疗效果更好。</p><sec id="s9_2_1"><title>5.2.1. 生理外科手术</title><p>生理外科技术主要用于早中期淋巴水肿的治疗。通过重建淋巴回流通道、处理受损的淋巴流出、为淋巴液创造一个替代流出通道、从远处的自体来源引入新的健康淋巴结组织作为带血管的游离组织移植到患肢以减轻淋巴水肿。包括淋巴管静脉吻合(LVAs)、血管化淋巴结移植(VLNT)、淋巴–淋巴搭桥等手术方式 [<xref ref-type="bibr" rid="hanspub.43090-ref20">20</xref>]。LVAs是通过显微外科将淋巴水肿肢体中的淋巴管与附近的小静脉连接起来，利用静脉系统来清除淤积在患肢的淋巴液，LVAs被用于ISL期I-II期患者，他们淋巴系统的一些功能仍然存在，因为淋巴系统的内在泵功能需要产生超过静脉系统的压力，以确保淋巴液流入静脉循环；对于ISL II-III期的患者，建议采用VLNT，VLNT可以从腋窝、腹股沟或颈部淋巴结盆内取材，也可以从腹腔内供体处取材，采集一个或数个淋巴结及其供应的血管，并将这些带血供的淋巴结组织移植到患肢中，VLNT通常被证明是安全的，但最常见的并发症是蜂窝织炎、淋巴管瘤、供体部位疼痛和血清瘤；淋巴-淋巴搭桥术是将功能正常的淋巴管从供体区域(通常是大腿内侧)直接缝合在受累肢体的淋巴管上；由于VLNT、淋巴–淋巴搭桥供体部位均有发生淋巴水肿的风险，外科医师积极寻找其他来源的血管化淋巴组织，比如腹腔镜下摘取附着在胃网膜血管供应上的带蒂组织瓣，并移植至下肢淋巴水肿区域，规避了供体部位发生淋巴水肿的可能性。</p></sec><sec id="s9_2_2"><title>5.2.2. 还原疗法</title><p>还原疗法适用于以纤维脂肪成分为主的晚期淋巴水肿患者，包括切除水肿组织和抽吸辅助蛋白脂肪切除(SAPL)。切除水肿组织是指对患部皮肤，皮下组织及其深筋膜进行切除，并在切除后行植皮术复原，能够较好的恢复患者的肢体形态和功能，缺点包括术后可能进ICU、美容效果差和复发 [<xref ref-type="bibr" rid="hanspub.43090-ref21">21</xref>]。抽脂术是指在患部吸取皮下淋巴液和脂肪，在手术后必须立即穿压缩服，并被鼓励无限期地穿压缩服 [<xref ref-type="bibr" rid="hanspub.43090-ref7">7</xref>]，抽脂术能够快速的达到治疗效果和美学效果，有文献报告了因下肢淋巴水肿而接受吸脂术的患者的体积减少超过50%，与原发性淋巴水肿相比，继发性淋巴水肿的体积缩小更大，除了体积减少之外，极大的改善了患肢的功能、感染率和患者生活质量。整体吸脂已证明有效和稳定的长期结果 [<xref ref-type="bibr" rid="hanspub.43090-ref22">22</xref>]，但抽脂术并不能治愈淋巴水肿，随着病情进展，淋巴液缓慢淤积，肢体肿胀可复发加重。</p><p>如果患者选择进行手术治疗，可建议患者在术前完成一个CDT疗程，以在手术前最佳地缓解受累区域的充血。手术后，鼓励患者进行术后CDT随访，以进一步减轻充血并处理术后潜在的水肿。这种持续的治疗可以使患者获得最佳的手术结果。</p></sec></sec></sec><sec id="s10"><title>6. 结论</title><p>综上所述，LLE对妇科癌症幸存者的身体、心理和社会健康都产生了负面影响，临床医师应对LLE引起重视，未来应在早期对患者进行明确的诊断和有效的干预，延缓下肢淋巴水肿的发生发展，以最大限度地提高患者的生活质量。目前对于妇科癌症患者术后LLE的预防和治疗，我们仍知之甚少，改善患者对疾病的了解和改善治疗依从性将直接改善疾病结果。复杂的降充血物理治疗是一种有效的非手术技术，通常需要终生的护理和管理。手术治疗可短期内有效减轻症状，减少蜂窝织炎的风险，改善功能和外观，但操作难度大、创伤大且费用高昂。不同的治疗方法的目的都是减少患肢的臂围、改善皮肤纤维化、预防或消除感染、改善患者生活质量，但LLE很难治愈且容易复发。更加标准化的临床诊断及多学科、个体化治疗方案的选择，将有助于改善疾病的预后。</p></sec><sec id="s11"><title>文章引用</title><p>胡怡林. 妇科恶性肿瘤术后下肢淋巴水肿的研究进展Study of Lower Extremity Lymphedema after Surgery for Gynecological Malignant Tumor[J]. 临床医学进展, 2021, 11(06): 2650-2655. https://doi.org/10.12677/ACM.2021.116383</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43090-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Russo, S., Walker, J.L., Carlson, J.W., et al. (2021) Standardization of Lower Extremity Quantitative Lymphedema Measurements and Associated Patient-Reported Outcomes in Gynecologic Cancers. Gynecologic Oncology, 160, 625-632. https://doi.org/10.1016/j.ygyno.2020.10.026</mixed-citation></ref><ref id="hanspub.43090-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yoshihara, M., Shimono, R., Tsuru, S., et al. (2020) Risk Factors for Late-Onset Lower Limb Lymphedema after Gynecological Cancer Treatment: A Multi-Institutional Retrospective Study. European Journal of Surgical Oncology, 46, 1334-1338. https://doi.org/10.1016/j.ejso.2020.01.033</mixed-citation></ref><ref id="hanspub.43090-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王健理, 姚德生. 妇科恶性肿瘤淋巴结清扫术后下肢淋巴水肿发病机制的研究进展[J]. 现代妇产科进展, 2019, 28(11): 864-868.</mixed-citation></ref><ref id="hanspub.43090-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Glaser, G., Dinoi, G., Multinu, F., et al. (2021) Reduced Lymphedema after Sentinel Lymph Node Biopsy versus Lymphadenectomy for Endometrial Cancer. International Journal of Gynecological Cancer, 31, 85-91.  
https://doi.org/10.1136/ijgc-2020-001924</mixed-citation></ref><ref id="hanspub.43090-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rockson, S.G., Keeley, V., Kilbreath, S., et al. (2019) Cancer-Associated Secondary Lymphoedema. Nature Reviews Disease Primers, 5, 22. https://doi.org/10.1038/s41572-019-0072-5</mixed-citation></ref><ref id="hanspub.43090-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Lyons, D. and Skoracki, R. (2020) Lymphedema: Conventional to Cutting Edge Treatment. Seminars in Interventional Radiology, 37, 295-308. https://doi.org/10.1055/s-0040-1713447</mixed-citation></ref><ref id="hanspub.43090-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Skladman, R., Anolik, R.A. and Sacks, J.M. (2021) State-of-the-Art Lymphedema Surgery Treatment Program. Missouri Medicine, 118, 134-140.</mixed-citation></ref><ref id="hanspub.43090-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dessources, K., Aviki, E. and Leitao, M. (2020) Lower Extremity Lymphedema in Patients with Gynecologic Malignancies. International Journal of Gynecological Cancer, 30, 252-260. https://doi.org/10.1136/ijgc-2019-001032</mixed-citation></ref><ref id="hanspub.43090-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Executive Committee of the International Society of Lymphology (2020) The Diagnosis and Treatment of Peripheral Lymphedema: 2020 Consensus Document of the International Society of Lymphology. Lymphology, 53, 3-19.</mixed-citation></ref><ref id="hanspub.43090-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, L., Fan, A., Yan, J., et al. (2016) Combining Manual Lymph Drainage with Physical Exercise after Modified Radical Mastectomy Effectively Prevents Upper Limb Lymphedema. Lymphatic Research and Biology, 14, 104-108.  
https://doi.org/10.1089/lrb.2015.0036</mixed-citation></ref><ref id="hanspub.43090-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Do, J.H., Choi, K.H., Ahn, J.S., et al. (2017) Effects of a Complex Rehabilitation Program on Edema Status, Physical Function, and Quality of Life in Lower-Limb Lymphedema after Gynecological Cancer Surgery. Gynecologic Oncology, 147, 450-455. https://doi.org/10.1016/j.ygyno.2017.09.003</mixed-citation></ref><ref id="hanspub.43090-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王霞, 蔡慧媛, 游菁, 等. 复合理疗在妇科恶性肿瘤术后下肢淋巴水肿中的应用及效果评价[J]. 中国实用护理杂志, 2017, 33(31): 2432-2435.</mixed-citation></ref><ref id="hanspub.43090-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mukherjee, A., Nepiyushchikh, Z., Michalaki, E., et al. (2021) Lymphatic Injury Alters the Contractility and Mechanosensitivity of Collecting Lymphatics to Intermittent Pneumatic Compression. The Journal of Physiology, 599, 2699-2721. https://doi.org/10.1113/JP281206</mixed-citation></ref><ref id="hanspub.43090-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李科, 刘宁飞, 付兰芬, 等. 烘绑疗法治疗肢体慢性淋巴水肿[J]. 组织工程与重建外科杂志, 2014, 10(2): 92-95.</mixed-citation></ref><ref id="hanspub.43090-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王江, 王子明. 七叶皂甙钠注射液配合利尿剂治疗下肢淋巴水肿临床观察[J]. 湖北中医杂志, 2010, 32(7): 49-50.</mixed-citation></ref><ref id="hanspub.43090-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Cormier, J.N., Askew, R.L., Mungovan, K.S., et al. (2010) Lymphedema beyond Breast Cancer: A Systematic Review and Meta-Analysis of Cancer-Related Secondary Lymphedema. Cancer, 116, 5138-5149.  
https://doi.org/10.1002/cncr.25458</mixed-citation></ref><ref id="hanspub.43090-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Badger, C., Preston, N., Seers, K., et al. (2004) Benzo-Pyrones for Reducing and Controlling Lymphoedema of the Limbs. Cochrane Database of Systematic Reviews, No. 2, Cd003140.  
https://doi.org/10.1002/14651858.CD003140.pub2</mixed-citation></ref><ref id="hanspub.43090-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">马跃海, 胡莹, 李秋华, 等. 中药内服外治联合淋巴引流技术治疗中老年恶性肿瘤术后下肢淋巴水肿临床疗效研究[J]. 实用药物与临床, 2017, 20(5): 520-523.</mixed-citation></ref><ref id="hanspub.43090-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ramachandran, S., Chew, K.Y., Tan, B.K., et al. (2021) Current Operative Management and Therapeutic Algorithm of Lymphedema in the Lower Extremities. Asian Journal of Surgery, 44, 46-53.  
https://doi.org/10.1016/j.asjsur.2020.08.010</mixed-citation></ref><ref id="hanspub.43090-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Garza, R., Skoracki, R., Hock, K., et al. (2017) A Comprehensive Overview on the Surgical Management of Secondary Lymphedema of the Upper and Lower Extremities Related to Prior Oncologic Therapies. BMC Cancer, 17, 468.  
https://doi.org/10.1186/s12885-017-3444-9</mixed-citation></ref><ref id="hanspub.43090-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sapountzis, S., Ciudad, P., Lim, S.Y., et al. (2014) Modified Charles Procedure and Lymph Node Flap Transfer for Advanced Lower Extremity Lymphedema. Microsurgery, 34, 439-447. https://doi.org/10.1002/micr.22235</mixed-citation></ref><ref id="hanspub.43090-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Schaverien, M.V. and Coroneos, C.J. (2019) Surgical Treatment of Lymphedema. Plastic and Reconstructive Surgery, 144, 738-758. https://doi.org/10.1097/PRS.0000000000005993</mixed-citation></ref></ref-list></back></article>